Vancomycin-Resistant Enterococcus faecium Infections Pipeline Review, H2 2015 Is Released Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2015 , provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Enterococcus Faecium Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vancomycin1
Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173372/vancomycinresistant-enterococcus-faecium-infections-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173372/vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2015 Table of Contents
Introduction 9 Global Markets Direct Report Coverage 9 Vancomycin-Resistant Enterococcus faecium Infections Overview 10 Therapeutics Development 11 Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11 Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies 13 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 19 Vancomycin-Resistant Enterococcus Universities/Institutes 21
faecium
Infections
-
Products
under
Investigation
by
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 22 Alchemia Limited 22
2
Alvogen Korea 23 Aphios Corporation 24 BioSource Pharm, Inc. 25 Cellceutix Corporation 26 Helix BioMedix, Inc. 27 Hsiri Therapeutics, LLC 28 LegoChem Biosciences, Inc 29 Lytix Biopharma AS 30 MGB Biopharma Limited 31 Microbiotix, Inc. 32 MicuRx Pharmaceuticals, Inc. 33 NovaBay Pharmaceuticals, Inc. 34 NovoBiotic Pharmaceuticals, LLC 35 Oragenics, Inc. 36 Sealife PHARMA GMBH 37 Sentinella Pharmaceuticals, Inc. 38 TAXIS Pharmaceuticals, Inc. 39 Wockhardt Limited 40 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 auriclosene - Drug Profile 50 Product Description 50 3
Mechanism of Action 50 R&D Progress 50 brilacidin tetrahydrochloride - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BSPC-728 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 chrysophaentin - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 closthioamide - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Epimerox - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 HB-1345 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58
4
HT-01 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 HT-02 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 IBN-1 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LCB-010371 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 LCB-010699 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 LTX-109 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Marinus - Drug Profile 68 Product Description 68 Mechanism of Action 68 5
R&D Progress 68 MBX-1162 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MGBBP-3 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 MRX-I - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 MRX-IV - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MU-1140 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 NAI-107 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 NAI-603 - Drug Profile 77
6
Product Description 77 Mechanism of Action 77 R&D Progress 77 SLP-0904 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SLP-0905 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 7
SP-2078 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Teixobactin - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 WCK-4086 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates 89 Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 104 Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 105 Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 106 Featured News & Press Releases 106 Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial for Novel Antibiotic MRX-I 106 Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 106 Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress towards Commercial Production of Lead Lantibiotic MU1140 107 Sep 12, 2012: NovaBay Pharma Announces Data from New Study Demonstrating Chemical Impact of Nchlorotaurine And NVC-422 On Bacterial Toxins 107 May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 108 Apr 23, 2012: MicuRx Completes Phase I Trial for MRX-I 108 Appendix 109 Methodology 109 8
Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110
Read More http://www.idatainsights.com/reports-landing-page.php?id=173372/vancomycinresistant-enterococcus-faecium-infections-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
9
10